---
figid: PMC7412855__bvaa075f0001
figtitle: Signaling pathways and molecular alterations in adrenal Cushing syndrome
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC7412855
filename: bvaa075f0001.jpg
figlink: pmc/articles/PMC7412855/figure/F1/
number: F1
caption: Signaling pathways and molecular alterations in adrenal Cushing syndrome.
  Physiologically, adrenocorticotropic hormone (ACTH) binds to a G protein窶田oupled
  receptor, the melanocortin receptor (MC2R), resulting in Gs protein activation.
  This in turn activates adenylate cyclase (AC) leading to cyclic adenosine monophosphate
  (cAMP) production. Four cAMP molecules bind to the protein kinase A (PKA) regulatory
  subunits dimer, which allows the release and activation of the 2 catalytic subunits
  of PKA. The free catalytic subunits will phosphorylate the transcription factor
  CREB (cAMP response element-binding protein), stimulating the transcription of several
  cAMP-dependant genes. Phosphodiesterases (PDE) involved in cAMP degradation are
  negative regulators of this pathway.Here is the list of molecular alterations disrupting
  cAMP/PKA signaling pathway which have been reported in the different etiologies
  of adrenal Cushing syndrome (mentioned in italics). 1. Activating mutation of MC2R
  (PBMAH)2. Activating mutation of GNAS1 (germline mutation in McCune-Albright syndrome
  and somatic mutation in unilateral cortisol-secreting adenoma)3. Illegitimate G
  protein窶田oupled receptors expression (PBMAH)4. Phosphodiesterase (PDE11A and/or
  PDE8B)- inactivating mutations (PPNAD and PBMAH)5. PRKACA duplication (bilateral,adrenal
  hyperplasia/micronodular and macronodular forms)6. PRKAR1A-inactivating mutations
  or deletion (germline mutation and somatic second hit)(PPNAD)7. Activating somatic
  mutation of PRKACA (unilateral cortisol-secreting adenoma)Apart from cAMP/PKA pathway:8.
  ARMC5 inactivation (germline mutation and somatic second hit) reducing steroidogenesisand
  adrenocortical cells apoptosis (PBMAH)
papertitle: Molecular Basis of Primary Aldosteronism and Adrenal Cushing Syndrome.
reftext: Patricia Vaduva, et al. J Endocr Soc. 2020 Sep 1;4(9):bvaa075.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9192545
figid_alias: PMC7412855__F1
figtype: Figure
redirect_from: /figures/PMC7412855__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7412855__bvaa075f0001.html
  '@type': Dataset
  description: Signaling pathways and molecular alterations in adrenal Cushing syndrome.
    Physiologically, adrenocorticotropic hormone (ACTH) binds to a G protein窶田oupled
    receptor, the melanocortin receptor (MC2R), resulting in Gs protein activation.
    This in turn activates adenylate cyclase (AC) leading to cyclic adenosine monophosphate
    (cAMP) production. Four cAMP molecules bind to the protein kinase A (PKA) regulatory
    subunits dimer, which allows the release and activation of the 2 catalytic subunits
    of PKA. The free catalytic subunits will phosphorylate the transcription factor
    CREB (cAMP response element-binding protein), stimulating the transcription of
    several cAMP-dependant genes. Phosphodiesterases (PDE) involved in cAMP degradation
    are negative regulators of this pathway.Here is the list of molecular alterations
    disrupting cAMP/PKA signaling pathway which have been reported in the different
    etiologies of adrenal Cushing syndrome (mentioned in italics). 1. Activating mutation
    of MC2R (PBMAH)2. Activating mutation of GNAS1 (germline mutation in McCune-Albright
    syndrome and somatic mutation in unilateral cortisol-secreting adenoma)3. Illegitimate
    G protein窶田oupled receptors expression (PBMAH)4. Phosphodiesterase (PDE11A and/or
    PDE8B)- inactivating mutations (PPNAD and PBMAH)5. PRKACA duplication (bilateral,adrenal
    hyperplasia/micronodular and macronodular forms)6. PRKAR1A-inactivating mutations
    or deletion (germline mutation and somatic second hit)(PPNAD)7. Activating somatic
    mutation of PRKACA (unilateral cortisol-secreting adenoma)Apart from cAMP/PKA
    pathway:8. ARMC5 inactivation (germline mutation and somatic second hit) reducing
    steroidogenesisand adrenocortical cells apoptosis (PBMAH)
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - gs
  - ac
  - dnc
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - Mp
  - CrebB
  - CrebA
  - POMC
  - GNAS
  - GNAL
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - ALDH7A1
  - PDE2A
  - PDE9A
  - PDE10A
  - PDE11A
  - PDE1A
  - PDE1B
  - PDE1C
  - PDE3A
  - PDE3B
  - PDE4A
  - PDE4B
  - PDE4C
  - PDE4D
  - PDE6A
  - PDE6B
  - PDE6C
  - PDE7A
  - PDE7B
  - PDE8A
  - PDE8B
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - GEM
  - KIR3DL1
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - ARMC5
  - AMP
  - H
  - GS
---
